

Sept. 15, 2021

Good Evening Everyone,

First, thank you for being patient with us as we maneuver the recent changes to the ordering process for monoclonal therapies. All remaining allocations will be ordered tonight, and sites will be notified tomorrow if their orders were approved or denied.

Second, for all future questions regarding mAbs, please email the OSDH Therapeutics Team at [hpp@health.ok.gov](mailto:hpp@health.ok.gov). This will allow for a faster response to questions. If you email me, I will then forward the email to [hpp@health.ok.gov](mailto:hpp@health.ok.gov) and this may further delay a response.

I want to provide you with some information regarding how we currently plan to assess/approve requests for mAbs and the factors we will consider in allocating mAbs. I apologize for the long email, but there is a large amount of information to share.

#### Ordering Processes

1. OSDH mAbs Ordering Portal: <https://tinyurl.com/OKMonoclonals>
2. HHS will notify OSDH of our WEEKLY allotment each Tuesday. The goal from OSDH is to have all orders submitted to AmerisourceBergen by close of business on the following Wednesday.
3. The OSDH portal for ordering will be open to submit requests Thursday - Monday and will be filled from the allocation on the following Tuesday and Wednesday. ANY orders placed on Tuesdays and Wednesdays will be discarded and will not be considered. All sites that submit orders Thursday-Monday will receive an email notifying them as to whether or not they received an allotment form that cycle no later than the following Thursday.
4. Ordering is NOT first come, first served. Ordering will be open every Thursday - Monday for the next allocation cycle and ALL orders submitted in that time frame will be considered. However...
5. Facilities should only submit one request per weekly cycle. It is very likely OSDH will not be in a position to make contact with sites to ask questions about requests, and if multiple requests are submitted from a single facility, the requests may be discarded.
6. If your facility inadvertently submits multiple requests, please email [hpp@health.ok.gov](mailto:hpp@health.ok.gov).
7. All sites should request the amount of product they anticipate using. OSDH is unable to guarantee your request will be met fully, but we will work to ensure mAbs are appropriately accessible across the state.
8. There is not yet a mechanism in place for ordering etesivimab to pair with any existing stock of bamlanivimab. OSDH is only able to allocate full course sets of the bamlanivimab/etesivimab combo therapy. AmerisourceBergen and HHS are currently working to find a solution for this.
9. Ordering for the first cycle has closed, however, all orders placed between tomorrow, 16 Sep and Monday, 20 Sep will be considered for the allocation that drops on Tuesday, 21 Sep.

#### Allocation Determinations:

1. HHS is utilizing COVID caseload, hospitalizations, and utilizations to determine how much we are going to be allocated.

2. OSDH will then consider the same factors within the state to determine where product can and will best be utilized.
3. If your site is not currently reporting, please email [hhs-protect@teletracking.com](mailto:hhs-protect@teletracking.com) to request an account. OSDH is unable to assist with Teletrack accounts.
4. OSDH will likely be unable to fill full requests for the next few weeks. We had roughly 11 days of most orders being denied and the approved orders were not fully met. This has resulted in a statewide deficit for mAbs. As I stated in an earlier email, OK was allocated roughly a fifth of what had been ordered in those 11 days. Please be patient as we work to determine best courses of action.

#### Shipping:

1. At this time, there is not a process to notify sites of shipping information.
2. AmerisourceBergen has a tracking tool that has been used in the past to search for shipping information. I can't guarantee this will work during the allocation process, and if it determined that it doesn't, OSDH will work to find a solution. The Tracking Tool can be found at <https://asdorder.amerisourcebergen.com/btstoreui/trackmyshipment>
3. AmerisourceBergen has indicated their goal to have all cycle allocations delivered by the second Friday following the cycle week. So for this first cycle, all allocations should be received by Friday, September 24th.
4. AmerisourceBergen plans to have set days for each state to have shipments sent out. We do not yet know what Oklahoma's day will be and that system will likely not be in motion until the week after next at the earliest.

#### How we can work together:

1. Facilities providing mAbs should be prioritizing patients that are symptomatic and at high risk of developing severe symptoms of COVID.
2. Clinicians should still use their professional judgement and the eligibility requirements in making decisions on providing patients with mAbs therapy for COVID treatment.
3. If your facility has an abundance of supply, you are encouraged to share with sites that do not have enough supply to support the demand, or work with facilities to accept patients in need of mAbs therapy.
4. Do not stockpile mAbs. Use what you have or work with other facilities to use what you have. If Oklahoma does not utilize what is allocated, we will be at risk of receiving less on the next allocation cycle.
5. If you are a facility in need of finding a nearby provider with stock, please reach out to your RMRS. If you do not know who your RMRS contacts are, please email [hpp@health.ok.gov](mailto:hpp@health.ok.gov) to request the information.
6. OSDH has our own mAbs locator tool for Oklahoma facilities. We will be working over the next week to include additional information that will assist providers and medical partners in finding mAbs providers that will be most suitable for patients. The locator tool can be found at <https://osdh.maps.arcgis.com/apps/dashboards/482ed39d24bc4ae597ce0e0a7f1193b7>. If your facility is listed and contains inaccurate information, please email [hpp@health.ok.gov](mailto:hpp@health.ok.gov).

#### Reporting Utilization:

1. If you haven't quite gathered, reporting utilization is going to be a critical aspect of the allocation process.
2. If sharing between sites, the facilities working together MUST make a determination on who will report the utilization. Please do not share between sites unless this is known. I cannot stress enough that if we don't accurately report utilization, we are likely to receive smaller allocations which will only further the challenges we are currently facing.
3. If you don't know who reports data in Teletrack for your facility, please email OSDH at [hpp@health.ok.gov](mailto:hpp@health.ok.gov), and we will work to figure out a point of contact so you can ensure there are no discrepancies in your facility's reported data.
4. Sites will need to reach out to [hhs-protect@teletracking.com](mailto:hhs-protect@teletracking.com) for any other needed assistance in reporting challenges. There is very little I can do to assist in Teletrack specific information.

New Accounts - Information will be coming soon. There will be no new sites added during this first cycle of allocations.

Quick Look References From Above:

1. New OSDH Therapeutics email: [hpp@health.ok.gov](mailto:hpp@health.ok.gov)
2. OSDH mAbs ordering portal: <https://tinyurl.com/OKMonoclonals>
3. AmerisourceBergen Tracking  
Tool: <https://asdorder.amerisourcebergen.com/btstoreui/trackmyshipment>
4. OSDH OK mAbs Locator  
Tool: <https://osdh.maps.arcgis.com/apps/dashboards/482ed39d24bc4ae597ce0e0a7f1193b7>

I know I've said it before, but please know we truly appreciate all that you are doing. If you have any questions, please reach out to the OSDH Therapeutics Team at [hpp@health.ok.gov](mailto:hpp@health.ok.gov).

Respectfully,

*Elyce M. Holloway*

State Hospital Preparedness Program (HPP) Coordinator

[Emergency Preparedness & Response Service](#)

Oklahoma State Department of Health

Office: 918.409.0781

Cell: 918.758.8579

Fax: 405.271.5143

CONFIDENTIALITY This e-mail, and any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender, by reply e-mail and destroy all copies of the original message.